Cita APA

Sun, J., Shen, L., Shah, M., Enzinger, P., Adenis, A., Doi, T., . . . Investigators., K. (2021). Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study.

Citación estilo Chicago

Sun, JM, et al. Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-controlled, Phase 3 Study. 2021.

Cita MLA

Sun, JM, et al. Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-controlled, Phase 3 Study. 2021.